Clowes Howard
Known title: DirectorCIK: 0001806992
Clowes Howard's purchase track record
Clowes Howard has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/11/2024 | CNSY | $7K | pending | pending | — |
| 5/8/2024 | CNSY | $20K | pending | pending | — |
| 9/13/2023 | CNSY | $10K | pending | pending | — |
| 6/6/2023 | CNSY | $4K | pending | pending | — |
| 5/3/2023 | CNSY | $9K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CNSY | ▲ Buy | Option Exercise | 921 | $0 | 10/1/2026 | View on chart |
| CNSY | ▲ Buy | Option Exercise | 922 | $0 | 7/1/2026 | View on chart |
| CNSY | ▲ Buy | Open Market | 5,000 | $7K | 9/11/2024 | View on chart |
| CNSY | ▲ Buy | Open Market | 9,804 | $20K | 5/8/2024 | View on chart |
| CNSY | ▲ Buy | Open Market | 6,993 | $10K | 9/13/2023 | View on chart |
| CNSY | ▲ Buy | Open Market | 1,000 | $4K | 6/6/2023 | View on chart |
| CNSY | ▲ Buy | Open Market | 2,500 | $9K | 5/3/2023 | View on chart |
| CNSY | ▲ Buy | Open Market | 15,000 | $9K | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cerenome projects $1.55M in Q3 CNSide billings
Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.
Cerenome projects $1.55M in Q3 CNSide billings. Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.